Key Takeaways & Executive Findings
- •• • OSBPL2 overexpression reduced cholesterol content by HPLC-MS quantification, directly linking lipid transport to stemness suppression; this matters clinically because cholesterol-rich membrane microdomains are known to sustain oncogenic signaling, and targeting this axis could overcome therapy resistance in NSCLC. • • In peritoneal carcinomatosis models, mice injected with L-Osbpl2-transduced LLC cells (5×10^6 cells/100µL, n=10 per group) showed significantly fewer metastatic tumors after 3 weeks compared to L-Vector controls, demonstrating in vivo efficacy; this provides preclinical proof-of-concept for OSBPL2-based intervention against metastasis. • • OSBPL2 expression negatively correlated with tumor stage progression and lymph node metastasis in clinical specimens, with repression of ALDH1A1, CD133, and Nanog; this positions OSBPL2 as a prognostic biomarker and a potential companion diagnostic for stemness-targeted therapies. • • Tumor sphere formation and stemness marker expression were significantly suppressed by OSBPL2-mediated lipid transportation, with experiments repeated three times and analyzed by one-way ANOVA or Student’s t-test (means ± s.e.m.); this robustness supports further development of OSBPL2 agonists or lipid-modulating agents as adjuvant treatments.
China Biomedical & Cell Therapy Radar
Get verified English translations, SEM micrographs & open-access PDF alerts from China's leading state key laboratories delivered to your inbox every Monday at 08:00 EST.
Abstract
Lung cancer remains the leading cause of cancer mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of diagnoses. Lung cancer stem-like cells (LCSCs) drive metastasis, recurrence, and therapeutic failure, yet effective targeting strategies remain elusive. Oxysterol-binding protein-like 2 (OSBPL2/ORP2) is a lipid transport protein that localizes to lipid droplets (LDs) and regulates cholesterol homeostasis, but its role in lung cancer stemness has not been defined. Here, we demonstrate that OSBPL2 reduces cellular cholesterol content, as quantified by HPLC-MS, and inhibits lipid droplet accumulation in lung cancer cells. OSBPL2-mediated lipid transportation significantly suppressed tumor sphere formation, stemness marker expression (ALDH1A1, CD133, Nanog), and in vivo tumorigenesis and metastasis. In peritoneal carcinomatosis models using BALB/c mice (n=10 per group) injected with L-Osbpl2 or L-Vector transduced LLC cells (5×10^6 cells/100µL), OSBPL2 overexpression reduced metastatic tumor burden. Clinical specimen analysis revealed that OSBPL2 represses LCSC marker expression and its level negatively correlates with tumor stage progression and lymph node metastasis. These findings establish OSBPL2 as a critical regulator of lung cancer stemness through lipid metabolic reprogramming, offering a potential therapeutic target for aggressive NSCLC.
1. Introduction
Lung cancer remains the leading cause of cancer-related mortality globally, with NSCLC comprising approximately 85% of cases. Cancer stem cells, particularly lung cancer stem-like cells (LCSCs), are pivotal drivers of metastasis, recurrence, and resistance to conventional therapies. Despite advances in targeted therapy and immunotherapy, effective strategies to eradicate LCSCs are lacking, representing a major clinical bottleneck. LCSCs exhibit stemness properties including self-renewal, differentiation, and expression of markers such as ALDH1A1, CD133, and Nanog, which contribute to therapeutic failure.
Oxysterol-binding protein-like 2 (OSBPL2/ORP2) is a lipid transport protein that localizes to lipid droplets and regulates cholesterol homeostasis. While lipid metabolic reprogramming is increasingly recognized as a hallmark of cancer, the specific role of OSBPL2 in lung cancer stemness has remained unexplored. This study addresses that gap by investigating whether OSBPL2-mediated lipid transportation can suppress LCSC properties. Using HPLC-MS lipidomics, in vitro sphere formation assays, and in vivo peritoneal carcinomatosis models, we demonstrate that OSBPL2 reduces cholesterol content, inhibits lipid droplet accumulation, and attenuates stemness and aggressiveness. These findings provide a mechanistic link between lipid metabolism and lung cancer stemness, offering a potential therapeutic target.
Loading authentic research manuscript (Pages 1–5)...
LIU Hongtao, YIN Pei, BIAN Guangliang, XU Caihua, WANG Ying (2026). OSBPL2-Mediated Lipid Transport Suppresses Stemness and Aggressiveness in Lung Cancer via Cholesterol Homeostasis and Lipid Droplet Regulation. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-026-04919-4
Research & Educational Purpose Only: The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioDataare intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the quantitative impact of OSBPL2 on cholesterol content and lipid droplet accumulation, and how does this translate to stemness inhibition?
OSBPL2 overexpression significantly reduced cholesterol content as measured by HPLC-MS, and inhibited lipid droplet accumulation. This lipid transport modulation suppressed tumor sphere formation and stemness marker expression (ALDH1A1, CD133, Nanog). The exact percentage reduction in cholesterol was not reported, but the effect was statistically significant (p<0.05) across three independent experiments.
In the peritoneal carcinomatosis model, what were the specific tumor burden outcomes and sample sizes?
Male BALB/c mice (8-week-old, ~20 g) were randomized into two groups (n=10 each) and injected intraperitoneally with L-Osbpl2 or L-Vector transduced LLC cells (5×10^6 cells/100µL). After 3 weeks, peritoneal metastasis tumors were counted. OSBPL2 overexpression significantly reduced metastatic tumor numbers compared to controls, with no exclusions reported. Statistical analysis used Student’s t-test (means ± s.e.m.).
How robust is the in vitro data, and what statistical methods were employed?
Each experiment was repeated three times, and representative data are shown. All statistical analyses were performed using GraphPad 9.0. Data are displayed as means ± s.e.m. and calculated with one-way ANOVA (multi-groups) or Student’s t-test (two groups). The percentage of tumor-free mice was evaluated, though specific p-values for each assay were not provided in the excerpt.
What are the clinical correlations between OSBPL2 expression and lung cancer malignancy?
In clinical specimens, OSBPL2 repressed the expression of LCSC markers ALDH1A1, CD133, and Nanog. The level of OSBPL2 was negatively correlated with malignant features such as tumor stage progression and lymph node metastasis. This suggests OSBPL2 could serve as a prognostic biomarker, though the exact correlation coefficients and patient cohort size were not detailed in the provided text.
What are the scalability and translational challenges for targeting OSBPL2 in lung cancer therapy?
The study demonstrates proof-of-concept in mice, but scalability challenges include delivery of OSBPL2 agonists or gene therapy to tumor sites, potential off-target effects on lipid metabolism in normal tissues, and the need for human clinical trials. The lentiviral transduction method used in mice is not directly translatable; small molecule activators or lipid-modulating agents would require optimization for bioavailability and safety. Cost parity with existing therapies remains unassessed.
Related Chinese Research & Cross-Citations
Isorhamnetin-preconditioned MSC-derived exosomes restore ovarian function by inhibiting ferroptosis in chemotherapy-induced POF
Background Chemotherapy-induced premature ovarian failure (POF) is a major cause of infertility, with limited treatment options. Mesenchymal stem cell-derived exosomes (MSC-Exos) have therapeutic potential. This study investigated whether preconditioning MSCs with the antioxidant flavonoid isorhamnetin (ISO) enhances the efficacy of their exosomes (ISO-MSC-Exos) against POF. Methods A cyclophosphamide-induced POF rat model was established, and the role of the ferroptosis inhibitor ferrostatin-1 was evaluated. MSC-Exos and ISO-MSC-Exos were isolated by ultracentrifugation and administered via tail vein injection. Ovarian recovery was assessed by monitoring the oestrous cycle, serum hormone levels, and histological findings. Lipid peroxidation and iron metabolism were evaluated by quantifying malondialdehyde, glutathione, iron deposition, and mitochondrial ultrastructure. Immunohistochemistry was used to assess the expression levels of GPX4, ACSL4, and FTH1. Proteomic analyses were performed to explore the underlying mechanisms. Results Ferroptosis plays a pivotal role in the cyclophosphamide-induced POF rat model. Both exosome therapies improved ovarian function and suppressed ferroptosis, with ISO-MSC-Exos showing superior efficacy. ISO-MSC-Exos significantly restored hormone levels, ameliorated oestrous cycle disorders, reduced follicular atresia, and enhanced fertility. Furthermore, ISO-MSC-Exos more effectively elevated glutathione levels, reduced malondialdehyde and Fe2⁺ levels, and reversed the abnormal expression of ferroptosis-related proteins GPX4, ACSL4, and FTH1. Proteomic analysis suggested that ISO-MSC-Exos effectively inhibit ferroptosis by downregulating Alox15 and Tf, thereby reducing lipid peroxidation substrates and cellular iron uptake. This finding represents a potential molecular mechanism underlying their superior efficacy compared with that of MSC-Exos. Conclusions ISO-MSC-Exos showed superior efficacy compared with MSC-Exos in restoring ovarian function and inhibiting ferroptosis, suggesting that ISO pretreatment enhances the therapeutic effect of MSC-Exos in the POF
Peptide-based Wnt signal activation enables scalable production of clinical-grade patient-derived intestinal organoids for regenerative cell therapy
Background Gastrointestinal diseases often involve cellular damage, degeneration or dysfunction in the tract, frequently requiring surgical interventions risking complications and lowered quality of life. Regenerative medicine holds great promise in improving patient care and providing novel treatment options for previously irreparable and untreatable tissues. Despite the clinical potential of intestinal organoids as a resource for regenerative cell therapy and bioengineering, the lack of clinical-grade cultures has hampered further development. Moreover, strategies to efficiently and reliably expand clinical-grade cultures at the scale required for application is limited. Methods A GMP-compliant protocol was developed to generate patient-derived colonic organoids from endoscopic biopsies. Clinical-grade colonic organoids cultured and expanded in Type-I collagen were compared to conventional Matrigel cultured organoids. To improve the culture-, cost-, and time-efficiency of culture expansion, several strategies were developed including organoid area-based passaging, one well plate culture, and the incorporation of Wnt activating peptide, PG-008. Conventional recombinant WNT3A culture was compared to the peptide PG-008 culture using single cell RNA sequencing. Results Clinical-grade collagen cultured organoids exhibited similar culture efficiency to Matrigel. Organoid establishment rate from 60 patients using the GMP-compliant protocol was 82%. The incorporation of PG-008 significantly enhanced organoid growth and stabilized patient-patient variability through intestinal stem cell (ISC) enrichment. Single cell RNA sequencing revealed that PG-008 resulted in remarkably pure culture consisting of ISCs
Targeting p75NTR activity alleviates the neurotoxic effect of high glucose on iPSC-derived dopaminergic neurons
Background: Hyperglycemia, a hallmark of diabetes mellitus, is a metabolic condition that highly affects the nervous system. While evidence from epidemiological and animal studies links diabetes to dopaminergic dysfunction and an increased risk of Parkinson’s disease, the underlying mechanisms remain unclear. Here, we examined the effects of high glucose on human iPSC-derived dopaminergic neurons and glial cells to better understand the pathogenic alterations that lead to neurotoxicity. Previous implication of neurotrophins in the neurological manifestations of diabetes prompted us to focus on the role of p75NTR neurotrophin receptor (p75NTR) in dopaminergic neurodegeneration under hyperglycemic conditions. Methods: iPSC-derived dopaminergic neurons, astrocytes and microglia were treated with high glucose (50mM, 100mM) for 48 h to simulate hyperglycemia. Cytotoxicity assays, RNA sequencing and DNA damage assessments were employed to investigate the pathological alterations induced by high glucose exposure in neurons. Pharmacological targeting of p75NTR activity allowed investigation of its involvement in glucose neurotoxicity. Glial-mediated neurotoxicity was evaluated using conditioned media and inflammatory marker analysis. Results: High glucose treatment led to DNA damage, activation of JNK signaling and cell death in neurons. Importantly, we observed upregulation of p75NTR and its pro-apoptotic ligand pro-NGF, suggesting activation of the pro-NGF/p75NTR axis in high glucose-treated neurons. Inhibition of p75NTR activity rescued neuronal cell death, identifying p75NTR as a central mediator of glucose neurotoxicity. Furthermore, glucose overload sensitized neurons to 6-hydroxydopamine (6-OHDA), increasing their vulnerability to neurotoxic insults—an effect reversed by p75NTR blockade. Treatment with BNN27, a synthetic NGF mimetic, prevented neuronal loss through p75NTR and TrkA receptors, suggesting neurotrophin signaling as a potential therapeutic target for combating high glucose-induced neuronal damage. Finally, we demonstrated the contribution of glial cells to neurodegeneration since high glucose
Serial brain FDG-PET and IMZ-SPECT following intracerebral MSC transplantation in patients with subacute ischemic stroke
Ischemic stroke is a leading cause of mortality and long-term neurological disability worldwide, and cell-based therapies represent a promising approach. Although clinical studies have reported favorable outcomes following cell transplantation, the effects on host neuronal integrity remain incompletely understood. This study investigated temporal and spatial changes in fluorodeoxyglucose positron emission tomography (FDG-PET) and 123I-iomazenil single-photon emission computed tomography (IMZ-SPECT) after intracerebral cell transplantation in patients with subacute ischemic stroke and examined their relationship with functional recovery. Seven adults with severe post-stroke disability underwent autologous mesenchymal stromal cell (HUNS001-01) transplantation 47–64 days after stroke onset. Brain FDG-PET and IMZ-SPECT were performed preoperatively and at 1, 3, and 12 months post-transplantation. Regions of interest were first manually set in the ipsilateral cortex where the 12-month postoperative-to-preoperative standard uptake value ratio seems increased, and followed by quantitative measurement. Five of seven patients demonstrated 5% or more increase of FDG-PET and/or IMZ-SPECT uptake in peri-infarct cortical regions, predominantly within the frontal or temporal cortex. Transplanted cells localized either within metabolically enhanced regions or in anatomically remote areas. FDG-PET and IMZ-SPECT changes were strongly interacted in each other and were associated with functional improvement. Overall, improvement of glucose metabolism and synaptic density/viability were observed in patient with subacute ischemic stroke, which may have been attributable to cell transplantation. Trial registration: UMIN000026130.
Beyond conventional PRP: a rationale for bioengineered, growth-factor-defined platelet mimetics in alopecia—the precision re-engineered efficacy optimization framework
Autologous platelet-rich plasma (PRP) is widely used for alopecia, but outcomes are often inconsistent due to procedural differences and patient-to-patient biological variability, including platelet yield, leukocyte content, and the mixed presence of stimulatory and inhibitory mediators. This commentary outlines a rationale for moving from variable autologous PRP toward defined PRP-inspired, growth-factor-based platelet mimetic formulations with batch-specified concentrations and relative proportions to enable more reproducible dosing and clearer clinical evaluation, aligned with Precision Re-Engineered Efficacy Optimization as a framework for standardizing potency, composition, and performance. Such formulations may improve consistency and scalability, but should be viewed as controlled reconstructions of selected PRP-associated signals rather than complete replicas of platelet releasate. Their translational value will depend on careful formulation characterization, staged proof-of-concept testing, and controlled clinical studies to establish safety, dosing, and comparative effectiveness.
PTPN2 deficiency amplifies inflammatory signalling and impairs functional maturation of human stem cell-derived islets
Background Protein tyrosine phosphatases (PTPs) play key roles in β-cell function and diabetes development. PTPN2 is a candidate gene for type 1 diabetes (T1D) that negatively regulates JAK/STAT signalling. However, the impact of PTPN2 deficiency on the differentiation and functionality of human stem cell-derived somatic metabolic cells remains unclear. Methods PTPN2 expression in β cells from T1D organ donors and during the differentiation of human stem cell-derived islets (SC-islets) was evaluated using single-cell RNA-Sequencing (scRNA-Seq) datasets. We differentiated CRISPR-Cas12a genome-edited PTPN2-deficient H1 human embryonic stem cells (H1-hESCs) into SC-islets, and scRNA-Seq was performed. The maturation and functionality of PTPN2-deficient SC-islets were assessed by implantation under the kidney capsule of NOD-SCID mice. Results scRNA-Seq analysis showed that PTPN2 expression was increased in β cells from recently diagnosed T1D and decreased in long-standing T1D organ donors compared with controls. Conversely, we found that PTPN2 expression was decreased at the early stages of SC-islet differentiation and reconstituted at the later stages, suggesting a developmental dynamic. PTPN2 deficiency exacerbated interferon-induced inflammatory signalling in stem cells and differentiated somatic metabolic cells. Interestingly, PTPN2 deficiency increased hedgehog signalling and reduced SC-islet differentiation efficiency in vitro. In addition, PTPN2-knockout SC-islets exhibited reduced glycaemic control after implantation in vivo, mediated by reduced endocrine cell identity and enhanced interferon signalling. Conclusions Our study postulates a key role of PTPN2 in preserving β-cell function during inflammatory and metabolic stress in SC-islets.